Payment overview · 2025
General Payments
$592.97
28 reported records · 15 companies
Healthcare provider profile · identity verified
Arleta A Kitlas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRADENTON, FL · NPI 1891985396
Verified facts
What the public records show
CMS Open Payments records show Arleta A Kitlas, MD received $592.97 in general payments during 2025 across 28 reported records.
GlaxoSmithKline, LLC. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $99.76 | 16.8% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.69 | 11.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.24 | 10.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.88 | 9.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.14 | 8.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.10 | 7.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.80 | 5.7% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $29.99 | 5.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.37 | 4.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $23.13 | 3.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.69 | 3.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.96 | 3.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.52 | 3.5% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $20.06 | 3.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.64 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $592.97 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $99.76 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.24 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.84 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $34.17 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.80 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $29.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 179 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 166 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
192 | 50 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
179 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
166 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
201 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
91 | 90 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1570 | 435 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1340 | 411 |
| Amlodipine Besylate | Amlodipine Besylate | 1122 | 319 |
| Losartan Potassium | Losartan Potassium | 1086 | 317 |
| Lisinopril | Lisinopril | 835 | 249 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 774 | 249 |
| Prednisone | Prednisone | 595 | 389 |
| Omeprazole | Omeprazole | 551 | 179 |
| Hydrochlorothiazide | Hydrochlorothiazide | 472 | 145 |
| Metformin Hcl | Metformin Hcl | 469 | 150 |
| Alprazolam | Alprazolam | 461 | 122 |
| Escitalopram Oxalate | Escitalopram Oxalate | 454 | 162 |
| Simvastatin | Simvastatin | 432 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 408 | 117 |
| Gabapentin | Gabapentin | 382 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 382 | 114 |
| Metoprolol Tartrate | Metoprolol Tartrate | 367 | 119 |
| Azithromycin | Azithromycin | 346 | 288 |
| Furosemide | Furosemide | 315 | 111 |
| Glipizide | Glipizide | 286 | 86 |
| Sertraline Hcl | Sertraline Hcl | 272 | 75 |
| Allopurinol | Allopurinol | 257 | 75 |
| Trazodone Hcl | Trazodone Hcl | 249 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 91 |
| Potassium Chloride | Potassium Chloride | 208 | 83 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 61 |
| Eliquis | Apixaban | 201 | 52 |
| Synthroid | Levothyroxine Sodium | 192 | 50 |
| Montelukast Sodium | Montelukast Sodium | 190 | 56 |
| Mounjaro | Tirzepatide | 179 | 37 |
| Meloxicam | Meloxicam | 178 | 61 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 63 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 70 |
| Atenolol | Atenolol | 167 | 48 |
| Spironolactone | Spironolactone | 167 | 55 |
| Ozempic | Semaglutide | 166 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 160 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 150 | 117 |
| Lorazepam | Lorazepam | 146 | 54 |
| Tramadol Hcl | Tramadol Hcl | 143 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 142 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 142 | 44 |
| Doxycycline Hyclate | Doxycycline Hyclate | 131 | 104 |
| Glimepiride | Glimepiride | 126 | 34 |
| Famotidine | Famotidine | 122 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 121 | 95 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 115 | 32 |
| Celecoxib | Celecoxib | 114 | 36 |
| Ezetimibe | Ezetimibe | 114 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 107 | 34 |
| Metformin Hcl Er | Metformin Hcl | 106 | 30 |
| Clonazepam | Clonazepam | 103 | 25 |
| Carvedilol | Carvedilol | 101 | 33 |
| Temazepam | Temazepam | 100 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 32 |
| Paxlovid | Nirmatrelvir/Ritonavir | 91 | 90 |
| Nebivolol Hcl | Nebivolol Hcl | 86 | 25 |
| Donepezil Hcl | Donepezil Hcl | 84 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 81 | 27 |
| Valsartan | Valsartan | 79 | 24 |
| Xarelto | Rivaroxaban | 77 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 20 |
| Propranolol Hcl | Propranolol Hcl | 75 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 73 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 42 |
| Finasteride | Finasteride | 72 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 32 |
| Mirtazapine | Mirtazapine | 68 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 68 | 24 |
| Diazepam | Diazepam | 66 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 54 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 62 | 15 |
| Bupropion Xl | Bupropion Hcl | 60 | 20 |
| Methylprednisolone | Methylprednisolone | 60 | 52 |
| Estradiol | Estradiol | 59 | 27 |
| Myrbetriq | Mirabegron | 59 | 19 |
| Benazepril Hcl | Benazepril Hcl | 58 | 14 |
| Calcitriol | Calcitriol | 57 | 14 |
| Alendronate Sodium | Alendronate Sodium | 56 | 16 |
| Valacyclovir | Valacyclovir Hcl | 56 | 29 |
| Glipizide Er | Glipizide | 52 | 15 |
| Januvia | Sitagliptin Phosphate | 52 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 16 |
| Bumetanide | Bumetanide | 49 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | 28 |
| Clonidine Hcl | Clonidine Hcl | 48 | 21 |
| Irbesartan | Irbesartan | 48 | 13 |
| Fenofibrate | Fenofibrate | 47 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 12 |
| Lovastatin | Lovastatin | 45 | 13 |
| Warfarin Sodium | Warfarin Sodium | 45 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 15 |
| Buspirone Hcl | Buspirone Hcl | 44 | 15 |
| Hydrocortisone | Hydrocortisone | 43 | 23 |
| Topiramate | Topiramate | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | 14 |
| Telmisartan | Telmisartan | 41 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 13 |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Nystatin | Nystatin | 40 | 29 |
| Labetalol Hcl | Labetalol Hcl | 39 | 11 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Cephalexin | Cephalexin | 38 | 34 |
| Chlorthalidone | Chlorthalidone | 38 | 11 |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Mupirocin | Mupirocin | 38 | 32 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 14 |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Methimazole | Methimazole | 37 | suppressed |
| Fluconazole | Fluconazole | 36 | 28 |
| Meclizine Hcl | Meclizine Hcl | 36 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Ramipril | Ramipril | 35 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 13 |
| Acyclovir | Acyclovir | 32 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Pregabalin | Pregabalin | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Jantoven | Warfarin Sodium | 28 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 20 |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Klor-Con 10 | Potassium Chloride | 20 | suppressed |
| Letrozole | Letrozole | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Np Thyroid | Thyroid,pork | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | 12 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 15 | 15 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Cefadroxil | Cefadroxil | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $592.97 · 28 records | GlaxoSmithKline, LLC. | AIRSUPRA, Auvelity, BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GEMTESA, MOUNJARO, MYFEMBREE, NP Thyroid 60, NURTEC ODT, Ozempic, Rybelsus, TARPEYO, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UNITHROID, VRAYLAR, Veozah, Wegovy, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error